Eli Lilly and Co EV/EBITDA
Data as of August 04, 2026
EV/EBITDA
31.82
Enterprise Value
$1.12T
EBITDA (TTM)
$35.19B
Sector
Pharmaceuticals
How It's Calculated
31.82 = $1.12T ÷ $35.19B
What This Means
Eli Lilly and Co's EV/EBITDA of 31.8 is elevated, which can reflect growth expectations, scarce assets, or cyclical EBITDA.
About Eli Lilly and Co
Eli Lilly and Co (LLY) operates in the Pharmaceuticals sector, specifically in Pharmaceuticals. With a market capitalization of about $1.08T, it ranks as a mega-cap stock — one of the largest publicly traded companies.
Shares recently traded near $1121.36, within a 52-week range of $623.78 to $1249.45 (-10.3% from the high, +79.8% from the low). Beta of 0.51 indicates relatively lower volatility versus the market.
Trailing profit margin is about 35.0%, signaling a strong profit margin relative to many peers.
Understanding This Metric
EV/EBITDA is widely used when comparing companies with different debt loads because enterprise value includes net debt while EBITDA approximates operating cash earnings power. For Eli Lilly and Co, the ratio should be read with growth, capex needs, and cycle position in Pharmaceuticals. Pair EV/EBITDA with free cash flow yield and net debt metrics before drawing conclusions — especially when EBITDA is depressed or boosted by one-time items.
Using This Number in Practice
Near 31.82x EV/EBITDA, Eli Lilly and Co (LLY) carries an elevated EV/EBITDA multiple that may embed growth expectations or scarcity within its peer set. Enterprise value of about $1.12T and EBITDA near $35.19B form the ratio — adjust for one-time items before treating the headline multiple as comparable.
Credit and LBO workflows often sort names on EV/EBITDA before drilling into free cash flow and maintenance capex. Pair this view with the EV/EBITDA calculator and the LLY metrics hub for related valuation pages.
Sector Comparison
Among Pharmaceuticals names on our S&P 100 coverage, Eli Lilly and Co's EV/EBITDA of 31.82 can be compared with peers such as JNJ (20.24), MRK (24.45), PFE (14.12). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Pharmaceuticals stocks.
Key Takeaways
- LLY is grouped in the Pharmaceuticals sector for peer comparisons.
- Recent beta of 0.51 suggests lower-than-market price sensitivity.
- Trailing profit margin of 35.0% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for LLY.
Learn the full workflow
Compare PE with PB, PEG, EV/EBITDA, and market cap in one structured path.
Open the Stock Valuation hub →Other LLY Metrics
Frequently Asked Questions
What is LLY's EV/EBITDA?
EV/EBITDA compares enterprise value to operating earnings before interest, taxes, depreciation, and amortization. Eli Lilly and Co's ratio is about 31.82 — common for comparing leveraged companies in Pharmaceuticals.
Is 31.82 high or low vs peers?
Among Pharmaceuticals peers (e.g. MRK (24.45), JNJ (20.24), PFE (14.12)), LLY's 31.82 should be read with growth, capex, and debt levels.
When is EV/EBITDA misleading?
EBITDA ignores capex, working capital, and stock-based comp; negative or tiny EBITDA makes the ratio meaningless. Cross-check with free cash flow and net debt.
Calculate the ev/ebitda for any stock with our free calculator.
Open EV/EBITDA Calculator →